Exane Derivatives Krystal Biotech, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
302Shares Held
24.5MCall Options Held
444KPut Options Held
325K-
Black Rock Inc. New York, NY3.95MShares$605 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$441 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$403 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$196 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$151 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.93B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...